ClinicalTrials.gg
RecruitingNCT07679113Updated Aug 10, 2026

IPG1094 Phase I Study for China Healthy Participants

A Phase 1 interventional study of IPG1094 Tablets in Healthy Volunteers, sponsored by Nanjing Immunophage Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This Phase 1 open-label study enrolls 24 healthy Chinese adults to investigate the pharmacokinetics, safety and tolerability of oral IPG1094 tablets. The trial includes two parts. Part A (12 participants) uses a crossover design to explore the impact of food on a single 200 mg dose of IPG1094; participants will receive the drug under fasting and post-meal conditions on separate days, with intensive blood sampling for PK analysis. Part B (12 participants) evaluates multiple-dose PK, where participants take 200 mg IPG1094 twice daily for 10 days to observe drug exposure and accumulation. All participants will undergo comprehensive safety checks such as lab tests, ECG and adverse event monitoring during screening, treatment and post-dosing follow-up. No placebo or blinding is applied in this study.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers,Phase 1, IPG1094, Pharmacokinetics, Safety,
03

In context

Lead sponsor

Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female healthy Chinese participants aged 18 to 50 years (inclusive).
  2. Comprehensive assessments including physical examination, vital signs, 12-lead , chest X-ray and laboratory tests are normal or with abnormalities judged not by the investigator.
  3. Body weight: Male ≥50.0 kg, Female ≥45.0 kg; (BMI) ranges from 19.0 to 26.0 (inclusive). BMI = Weight(kg) / Height(m)².
  4. Female participants are non-pregnant and non-lactating.
  5. Participants have no pregnancy plan and no sperm/egg donation plan from 2 weeks before screening to 6 months after the end of the study, and agree to use effective during this period.
  6. Voluntarily sign the written form, and fully understand the trial content and potential adverse reactions.

Exclusion criteria

Exclusion Criteria:

  1. History of severe cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological, psychiatric or other systemic diseases with clinical significance.
  2. interval >450 ms (male) or >470 ms (female).
  3. History of recurrent headache, nausea or vomiting.
  4. Blood loss ≥400 mL within 3 months before screening, or plan to donate blood during the study.
  5. History of orthostatic hypotension or dysphagia.
  6. History of gastrointestinal diseases affecting drug absorption.
  7. Lactose intolerance, special dietary restrictions, or unable to follow unified diet requirements during the trial.
  8. History of drug/food allergy, drug abuse or alcohol abuse.
  9. Heavy smoking, excessive intake of tea, coffee or caffeinated beverages within 3 months before screening.
  10. Use of any prescription drugs, over-the-counter drugs, health products or Chinese herbal medicines within 14 days before screening.
  11. Use of drugs affecting liver metabolism or gastrointestinal environment within 30 days before screening.
  12. Intake of citrus fruits/juices within 5 days before screening or during the trial.
  13. Participated in other clinical trials within 3 months before screening.
  14. Positive result of urine drug screen or breath alcohol test at admission.
  15. Difficulty in venous blood collection, history of syncope during blood collection.
  16. Acute illness before screening, or other conditions judged inappropriate for participation by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part A (Single-dose & Food Effect Group)

    Randomized open-label 2-way crossover single 200 mg IPG1094 tablet, evaluate food effect on PK; 6 subjects fast→fed, 6 subjects fed→fast.

    Drug: IPG1094 Tablets

  • Experimental
    Part B (Multiple-dose Group)

    Open-label multiple-dose IPG1094 200 mg BID oral for 10 consecutive days to assess steady-state PK, safety and tolerability.

    Drug: IPG1094 Tablets

Interventions

  • Part A:Oral administration with 240 mL water; fasted: ≥10h overnight fast, no water 1h before/after dosing; fed: take drug within 30 mins of finishing standardized high-fat breakfast. Single dose 200 mg per cycle, two cycles separated by 5-day washout. Part B:Oral 200 mg twice daily, morning \& evening, continuous 10 days; each dose taken with 240 mL water, restricted water intake 1h pre/post dose; steady-state PK sampling for accumulation assessment.

06

What researchers measure

Primary outcomes

  1. Part A:Time to maximum concentration (Tmax)

    The time elapsed from IPG1094 administration to the occurrence of Cmax under fasting and high-fat fed states, summarized by median values per treatment sequence.

    Time frame: Full PK sampling profiles on Day 1 and Day 6

  2. Part A:Plasma maximum concentration (Cmax)

    The maximum observed plasma concentration of IPG1094 after a single 200 mg oral dose under fasting and high-fat fed conditions, calculated via non-compartmental analysis (NCA).

    Time frame: Full PK sampling profiles on Day 1 and Day 6

  3. Part A:Terminal elimination half-life (t1/2)

    Description: Terminal elimination half-life of IPG1094 following single-dose administration in fasting and high-fat fed regimens, derived from the terminal log-linear elimination phase of concentration-time curves.

    Time frame: Serial blood samples collected up to 96 hours post-dose on Day 1 and Day 6

  4. Part B:Steady-state maximum plasma concentration (Css,max)

    The maximum observed steady-state plasma concentration of IPG1094 after continuous twice-daily 200 mg dosing for 10 days, calculated via non-compartmental analysis (NCA).

    Time frame: Full PK sampling profiles on Day 10

  5. Part B:Time to steady-state maximum concentration (Tss,max)

    The time elapsed after the Day 10 morning dose to reach steady-state peak concentration (Css,max), presented as descriptive statistics.

    Time frame: Full PK sampling profiles on Day 10

  6. Part B:Steady-state terminal elimination half-life (t1/2)

    Terminal elimination half-life of IPG1094 at steady state after repeated twice-daily dosing, calculated from the log-linear terminal elimination phase of Day 10 concentration-time curve.

    Time frame: Serial blood samples collected up to 72 hours post-dose on Day 10

Secondary outcomes

  1. Safety indicators:adverse event

    Time frame: PartA:From signed informed consent through Day 13 follow-up phone call PartB:From signed informed consent through Day 17 follow-up phone call

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679113
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Collaborators
Shanghai Xuhui Central Hospital
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Jul 30, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Anzhu Yu
Contact
azyu@immunophage.com.cn
+86-21-34782827

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MIF Inhibitor IPG1094

Start the discussion